Table 2.

Therapeutic nanoparticles under pre-clinical or clinical evaluation.

Nanostructure	Nanoparticle	Conjugated Drug	Evaluation	Ref
Dendrimer	Polyethylene glycol (PEG)-platinum	α-cyclodextrin	pre-clinical	[127]
	Polyamidoamine dendrimer	N-acetyl-cysteine	clinical/phase I	[128]
Micelle	Polypropylene sulfide-PEG- serine-folic acid zinc phtalocyanine	doxorubicin	pre-clinical	[129]
	PEG-polyaspartate polymeric micelle	paclitaxel	clinical/phase III	[130]
Carbon nanotube	PEGylated single walled CNT	epidermal growth factor (EGF), cisplatin	pre-clinical	[131]
Metallic nanoparticles	Hollow mesoporous copper sulfide nanoparticle with iron oxides	doxorubicin	pre-clinical	[132]
	Hollow mesoporous copper sulfide nanoparticle with hyaluronic acid	doxorubicin	pre-clinical	[133]
	PEGylated MoS nanosheets		pre-clinical	[134]
	Azo-functionalized magnetite nanoparticles	doxorubicin	pre-clinical	[135]
	PEGylated gold nanorods (AuNR)	doxorubicin	pre-clinical	[136]
	Iron oxide magnetic silica-gold nanoparticles		clinical/phase I	[137]
	PEGylated gold nanorod	aptamer	pre-clinical	[138]
Silica based nanoparticles	Peptide-functionalized mesoporous silica	lactobionic acid, doxorubicin	pre-clinical	[139]
	Transferrin mesoporous silica	doxorubicin	pre-clinical	[140]
	PEGylated mesoporous silica	amino-β-cyclodextrin, doxorubicin	pre-clinical	[141]
	mesoporous silica	cytochrome C conjugated lactobionic acid-doxorubicin	pre-clinical	[142]
	Hydroxyapatite nano-crystalline nano-structured silica gel		clinical/phase 0	[143]
Nanodiamonds	PEGylated nanodiamonds	doxorubicin	pre-clinical	[144]
	PEGylated nanodiamonds	irinotecan, curcumin	pre-clinical	[145]